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176Objectives: Undersized ring annuloplasty is the treatment of choice for functional mitral regurgitation.
However, recurrence of mitral regurgitation within the first years is frequent. The aim of this study was to
analyze the functional and clinical outcome after mitral valve repair with the 3-dimensional saddle-shaped
Edwards GeoForm (Edwards Lifesciences LLC, Irvine, Calif) annuloplasty ring in patients with ischemic mitral
regurgitation.
Methods: Between November 2006 and November 2012, 70 patients (mean age, 68  10 years; mean left
ventricular ejection fraction, 40% 15%) with functional mitral regurgitation due to ischemic cardiomyopathy
underwent mitral valve repair with the Edwards GeoForm annuloplasty ring. Concomitant procedures,
such as coronary artery bypass grafting (75.7%), tricuspid valve repair (25.7%), aortic valve replacement
(8.6%), and the Maze procedure (4.3%), were performed in 92.9% of patients. Follow-up is 97% complete
(mean, 3.0  1.7 years). Transthoracic echocardiography was obtained 2.4  1.7 years postoperatively.
Results: Thirty-day mortality was 5.9%. Overall survival at 5 years was 71.3%  6.9%. At 4 years, overall
freedom from recurrence of mitral regurgitation grade 3þ or greater was 92.5%  3.6%, and freedom from
recurrence of mitral regurgitation grade 2þ or greater was 71.0%  8.7%. Three patients required a mitral
valve–related reoperation for ring dehiscence. New York Heart Association functional class improved from
3.6  0.6 to 1.6  0.6 during follow-up (P< .05). Mean mitral valve pressure gradient was 3.3  1.8 mm
Hg across all ring sizes at the time of follow-up.
Conclusions:Mitral valve repair with the 3-dimensional saddle-shaped Edwards GeoForm annuloplasty ring in
case of ischemic mitral regurgitation shows a low rate of recurrent regurgitation at 4 years. Clinically relevant
mitral stenosis was not detected. The importance of secure anchoring of the device in the mitral annulus has to be
emphasized to prevent ring dehiscence. (J Thorac Cardiovasc Surg 2014;148:176-82)Functional mitral regurgitation (FMR) as a consequence of
regional or global left ventricular (LV) dysfunction despite
a structurally normal mitral valve (MV) is a common
complication in patients with ischemic heart disease or
idiopathic dilated cardiomyopathy.1 FMR is strongly
associated with adverse outcome in patients with both
ischemic and dilated cardiomyopathy.2 The survival of
patients with ischemic mitral regurgitation (IMR) was
30% after 5 years.2 Moreover, its presence increases
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The Journal of Thoracic and Cardiovascular Surg71% after surgical MV repair.3 To date, the optimal strategy
for the management of severe FMR is still controversial,
and current guidelines recommend surgical treatment
but do not indicate whether to repair or replace the MV.4
In a recently published meta-analysis by Vassileva and
colleagues,5 MV repair for IMR is associated with better
short- and long-term survival compared with MV replace-
ment. On the other hand, Maltais and colleagues6 showed
in a single-center study that the surgical technique did not
influence long-term survival in patients with ischemic
cardiomyopathy.
In case of MV repair, undersized ring annuloplasty is
currently used as the method of choice to treat FMR.7
Although early results with this technique are satisfactory,
late recurrence of FMR has been observed in a significant
number of patients.8,9 It is supposed that MV repair
with an increased coaptation length is associated with
more durable results, especially by application of an
annuloplasty ring with a reduced anteroposterior (A-P)
dimension.10 To address this issue, the GeoForm annulo-
plasty ring (Edwards Lifesciences LLC, Irvine, Calif)
was introduced to the market in 2005. The GeoFormery c July 2014
Abbreviations and Acronyms
AF ¼ atrial fibrillation
A-P ¼ anteroposterior
FMR ¼ functional mitral regurgitation
IMR ¼ ischemic mitral regurgitation
LV ¼ left ventricular
MV ¼ mitral valve
NYHA ¼ New York Heart Association
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distance (41% reduction compared with Carpentier-
Edwards Physio [Edwards Lifesciences LLC]). In addition
to the marked reduction of the A-P diameter, the
3-dimensional elevation of the ring in the middle of the
P2 segment (6-mm lift) raises the posterior MV annulus to
counteract the downward pull of the enlarged left ventricle
and compensates the restriction of the posterior leaflet.
The aim of the present study was to analyze the clinical
and functional outcome after MV repair with the GeoForm
annuloplasty ring in patients with IMR.MATERIALS AND METHODS
Inclusion Criteria
Between November 2006 and November 2012, 70 patients with FMR
due to ischemic cardiomyopathy underwent MV repair with the Edwards
GeoForm annuloplasty ring at the German Heart Center Munich. A
diagnosis of FMR was made in patients in whom MR was present with
regional wall motion abnormalities with normal valve leaflets and intact
papillary muscles (Carpentier Class IIIb). All patients with other types of
MR (ie, FMR due to dilated cardiomyopathy or degenerative MV disease)
or patients with endocarditis were excluded. Clinical symptoms,
hemodynamic data, and functional outcome were obtained from medical
records, patients’ follow-up visits, mailed questionnaires, telephone
interviews with the patient or family members, and communications
from the referring physicians.
Echocardiography
Echocardiographic examinations were performed with a Siemens
Sequoia Acuson System (Munich, Germany) using a 2.5-MHz imaging
transducer and included M-mode, continuous-wave 2-dimensional,
pulsed-wave Doppler, and color Doppler analyses. The severity of
regurgitation was classified as none/trivial (0þ), mild (1þ), moderate
(2þ), moderate-severe (3þ), or severe (4þ) and assessed in a semi-
quantitative manner by means of color Doppler flow mapping. For
detection of regurgitation, a color flow Doppler was used with a Nyquist
limit (aliasing velocity of 50–60 cm/sec) and a color gain that just
eliminated random color speckle from nonmoving areas. The vena
contracta was measured in the parasternal long-axis view as the narrowest
portion of the jet that occurred at the orifice. The color flow sector was as
narrow as possible with the least depth to maximize lateral and temporal
resolution. All evaluations were carried out according to standard
techniques recommended by the American Society of Echocardiography.11
Operative Technique
All operations were performed on cardiopulmonary bypass under
moderate systemic hypothermia (30C-32C). Myocardial protection
was achieved using cold (4C) antegrade crystalloid (Custodiol, KoehlerThe Journal of Thoracic and CaChemie; Alsbach-Haehnlein, Germany) or antegrade blood cardioplegia,
and the MV was exposed through a left atrial or a trans-septal approach,
depending on the preference of the surgeon.
Sizing was primarily based on the length of the anterior mitral leaflet.
Because of the significantly reduced A-P distance of the Edwards GeoForm
ring, downsizing is not necessary and was never performed. Thus, ring size
was chosen so that the provided sizer totally covered the anterior leaflet for
sufficient coaptation. In addition, the intertrigonal distance serves as an
additive tool to find an optimal correlation between the height and thewidth
of the anterior leaflet.
All patients were discharged with a regimen of phenprocoumon
(Marcumar; MEDA Pharma, Bad Homburg, Germany) for the first
3 months postoperatively. After 3 months, anticoagulant therapy was
continued only in patients with permanent atrial fibrillation (AF) or
severely depressed LV function.
Follow-up
Complete follow-up was achieved in 97.1% of patients (68/70),
yielding a cumulative total of 173 patient-years. The follow-up was
closed on January 31, 2013. As of January 2013, 55 patients are alive
(mean, 3.0  1.7 years). Postoperative complications were analyzed
according to the ‘‘Guidelines for Reporting Morbidity and Mortality after
Cardiac Valvular Operations’’ approved by the Society of Thoracic
Surgeons. The study protocol was approved by the local governmental
ethics committee (approval reference number: 5247/11).
Statistical Analysis
Statistical analysis was performed with IBM SPSS Statistics 21 (SPSS
Inc, Chicago, Ill). Continuous variables are reported as mean  standard
deviation or median (range) for skewed data. Categoric variables are
reported as absolute and relative frequencies. To test for changes in New
York Heart Association (NYHA) classification and MR grade, the sign
test was used. The Kaplan–Meier method was used to estimate overall
survival. Survival estimates are reported as the mean standard deviation.
All reported P values are 2 sided and have not been adjusted for multiple
testing.RESULTS
Preoperative Variables
The mean age at operation was 68  10 years
(range, 42-88 years), and 46 of 70 patients (65.7%) were
male. Preoperative clinical and hemodynamic data are
summarized in Table 1. Preoperative echocardiographic
assessment was performed in every patient by the referring
cardiologist and repeated after patients’ admission, usually
1 or 2 days before surgery. Eight patients (11.4%) showed
MR 4þ (vena contracta 7 mm), 55 patients (78.6%)
showed MR 3þ (vena contracta 5 mm and<7 mm), and
7 patients showed MR 2þ (vena contracta 3 mm and<5
mm). Thirty-seven patients (52.9%) had a history of preop-
erative myocardial infarction at an average of 5.5  8.0
years before the operation. The preoperative NYHA
functional class was assessed at the time of admission; 5
patients (7.1%) presented with NYHA class II, 21 patients
(30.0%) presented with NYHA class III, and 44 patients
(62.9%) presented with NYHA class IV. Five patients
(7.1%) had previous cardiac surgery other than on the MV.
All patients were preoperatively treated with medication
for congestive heart failure. Medication at the time ofrdiovascular Surgery c Volume 148, Number 1 177
TABLE 1. Preoperative data
No. of patients (n) 70
Male/female (n) 46/24
Age (y) 68  10
NYHA class (n,%)
II 5 (7.1)
III 21 (30.0)
IV 44 (62.9)
Preoperative rhythm (n,%)
Sinus rhythm 51 (72.9)
AF 12 (17.1)
Paced rhythm 7 (10.0)
LV ejection fraction (%) 40  15
Preoperative MV regurgitation (grade) 3.0  0.4
Previous myocardial infarction (n,%) 37 (52.9)
Previous cardiac operation (n,%) 5 (7.1)
Data shown are mean  SD. AF, Atrial fibrillation; LV, left ventricular; MV, mitral
valve; NYHA, New York Heart Association.
TABLE 2. Operative data
Operative mortality (n,%) 4 (5.9%)
Ring size (labeled) (n,%)
26 4 (5.7)
28 22 (31.4)
30 24 (34.3)
32 20 (28.6)
Concomitant procedures (n,%)
None 5 (7.1)
CABG 53 (75.7)
Tricuspid valve repair 18 (25.7)
Aortic valve surgery 6 (8.6)
AF ablation 3 (4.3)
Aortic crossclamp time (min) 96  28
Bypass time (min) 145  42
Intra-aortic balloon pump (n,%) 16 (22.9)
MV repair techniques (n,%)
Isolated ring annuloplasty 55 (78.6)
Chordal replacement anterior mitral leaflet
with PTFE sutures
7 (10.0)
Wooler-type suture 1 (1.4)
Chordal cutting 1 (1.4)
Pseudo-commissure closure 4 (5.7)
Combined techniques 2 (2.9%)
Data shown are mean  SD. AF, Atrial fibrillation; CABG, coronary artery bypass
grafting; MV, mitral valve; PTFE, polytetrafluoroethylene.
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Dadmission was as follows: Some 36% of patients were
treated with diuretics, angiotensin-converting enzyme
inhibitors, and beta-blockers, as recommended by the
European Society of Cardiology Guidelines for the
diagnosis and treatment of acute and chronic heart
failure 2012.12 Some 33% of patients were treated
with diuretics and beta-blockers, 8% of patients were
treated with angiotensin-converting enzyme inhibitors and
beta-blockers, 10% of patients were treated with
angiotensin-converting enzyme inhibitors and diuretics,
and 13% of patients were treated with only diuretics,
angiotensin-converting enzyme inhibitors, or beta-blockers.
Operative Data
Thirty-day mortality was 5.9% (n ¼ 4), attributed to low
cardiac output (n¼ 2) and septic multiorgan failure (n¼ 2).
A total of 5 patients (7.1%) underwent isolated MV repair,
and 65 patients (92.9%) underwent MV repair with a
concomitant cardiac procedure: coronary artery bypass
grafting (n ¼ 53), tricuspid valve surgery (n ¼ 18), and
aortic valve surgery (n ¼ 6). Nine patients underwent MV
repair in combination with coronary artery bypass grafting
and tricuspid or aortic valve surgery. The average ring size
was 29.7  1.8 mm. Table 2 shows the distribution of the
ring sizes for the entire cohort. The mean cardiopulmonary
bypass time was 145  42 minutes, and the mean aortic
crossclamp time was 96  28 minutes. Fifty-five patients
(78.6%) had an isolated ring implantation. If residual MR
was detected by water test during surgery, additional repair
techniques were applied in 15 patients (21.4%). Operative
data are summarized in Table 2.
Follow-up Data
All 70 patients had an echocardiographic assessment at
hospital discharge (65 patients) or during the hospital stay
(in case of hospital death, 5 patients) at a mean time of178 The Journal of Thoracic and Cardiovascular Surg7.8  3.7 days postoperatively. At this early echocardio-
graphic examination, MR was none/trivial (0þ/4þ) in
36 patients (51.4%), mild (1þ/4þ) in 29 patients
(41.4%), moderate (2þ/4þ) in 4 patients (5.7%), and
severe (4þ/4þ) in 1 patient (1.4%) who had immediate
reoperation. Two patients (2/70) were lost to follow-up
(completeness of follow-up 97.1%).
In total, 63 of 70 patients (5 in-hospital deaths,
2 patients lost to follow-up) had an echocardiographic
assessment at a mean of 2.4  1.7 years postoperatively
(range, 3 months to 5.6 years, except the patient with severe
MR, who underwent reoperation at postoperative day 11).
Echocardiographic follow-up is 100% complete.
Figure 1 shows a comparison of MR preoperatively, at
hospital discharge or during hospital stay (postoperatively),
and at latest follow-up of 63 of 70 patients (5 in-hospital
deaths, 2 patients lost), including echocardiography results
of 3 patients before reoperation.
At the latest echocardiographic examination, MR was
none/trivial (0þ/4þ) in 25 patients (39.7%), mild
(1þ/4þ) in 25 patients (39.7%), moderate (2þ/4þ) in 9
patients (14.3%), moderate-severe (4þ/4þ) in 1 patient
(1,6%), and severe (4þ/4þ) in 3 patients (4.8%) who had
reoperation. In these 3 patients, MV-related reoperation
was required 11 days, 6 months, and 7 months after the
initial operation. The indication for reoperation was
recurrent MR caused by ring dehiscence in the region of
the posterior ring (P2). At 4 years, Kaplan–Meier analysis
revealed 92.5%  3.6% freedom from recurrence of MRery c July 2014
FIGURE 1. Comparison of MR preoperatively, at hospital discharge or
during hospital stay (postoperatively), and at latest follow-up. Data of 63
of 70 patients (5 in-hospital deaths, 2 patients lost to follow-up), including
echocardiography results of 3 patients before reoperation. MR, Mitral
regurgitation.
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and 71.0%  8.7% freedom from recurrence of MR grade
2þ (ie, moderate).
Mean MV pressure gradients were 3.3  1.8 mm Hg
across all ring sizes at the time of follow-up. NYHA
functional class improved from 3.6  0.6 to 1.6  0.6
during follow-up (P< .05). LV ejection fraction assessed
by echocardiography increased from 40%  15%
(before surgery) to 50%  9% at latest follow-up. The
difference did not reach significance.
All patients were postoperatively treated with medication
for congestive heart failure. Medication at the time ofFIGURE 2. Kaplan–Meier estimate of freedom from recurrence of MR
grade 3þ to 4þ (ie, moderate-severe and severe) of 68 patients with
IMR who underwent MV repair with the Edwards GeoForm annuloplasty
ring (Edwards Lifesciences LLC, Irvine, Calif). MR, Mitral regurgitation.
The Journal of Thoracic and Cafollow-up was as follows: Some 68% of patients were
treated with diuretics, angiotensin-converting enzyme
inhibitors, and beta-blockers as recommended by the
European Society of Cardiology Guidelines for the
diagnosis and treatment of acute and chronic heart
failure 2012.12 Some 18% of patients were treated
with diuretics and beta-blockers, 6% of patients were
treated with angiotensin-converting enzyme inhibitors
and beta-blockers, 4% of patients were treated with
angiotensin-converting enzyme inhibitors and diuretics,
and 4% of patients were treated only with angiotensin-
converting enzyme inhibitors.
Eleven patients died late after a median time of 1.6 1.3
years (31 days to 3.6 years) after the operation. The cause of
death could be assessed in only 3 of 11 patients. Two
patients died of cardiac-related causes, and 1 patient died
of septic multiorgan failure. Overall survival at 5 years
was 71.3%  6.9% (Figure 3).DISCUSSION
The present study reports for the first time the
midterm results of a series of patients who underwent
MV repair with the new 3-dimensional Edwards GeoForm
annuloplasty ring in patients with IMR.
The main finding of this study is that freedom from
recurrence of MR grade 3þ to 4þ (ie, moderate-severe
and severe) was 92.5%  3.6% at 4 years, and freedom
from recurrence of MR grade 2þ (ie, moderate) was
71.0%  8.7% at 4 years.
The 3-dimensional GeoForm annuloplasty ring, first
introduced by Edwards in 2005, is a complete rigid ringFIGURE 3. Kaplan–Meier estimate of survival function for 68 patients
with IMR who underwent MV repair with the Edwards GeoForm
annuloplasty ring.
rdiovascular Surgery c Volume 148, Number 1 179
Acquired Cardiovascular Disease Guenzinger et al
A
C
Dand has a silicone-wrapped titanium core with velour cloth.
It is characterized by its reduced A-P distance (41%
reduction compared with the Carpentier-Edwards Physio),
which brings the annulus inward to counteract the outward
pull of the left ventricle. In addition, the elevation of the ring
at the P2 segment (6-mm lift) raises the MV apparatus to
counteract the downward pull of the enlarged left ventricle.
In a computational model of the MV, Maisano and
colleagues13 demonstrated that an annular prosthesis with
selective reduction in the A-P dimension is theoretically
more effective than a nonprofile ring for treating leaflet
tethering in FMR. However, recent studies in the normal
beating ovine heart suggested that 3-dimensional rigid
complete annuloplasty rings increase anterior mitral leaflet
strain, which may affect repair durability.14 To address
these issues, we analyzed the midterm results of a large
series of patients with FMR due to ischemic cardio-
myopathy who underwent MV repair with the Edwards
GeoForm annuloplasty ring.
Patients with ischemic or dilated cardiomyopathy often
develop FMR as a consequence of regional or global LV
dysfunction despite a structurally normal MV.1 IMR as a
consequence of myocardial infarction is caused by leaflet
tethering and restriction of motion, whereas dilative
MR is caused by annular enlargement and central
malcoaptation.15 The presence of FMR has a poor prognosis
with a clear relationship between MR severity and reduced
survival.16 Survival in patients with severe FMR and
medical management at 5 years is approximately
30%.2,16,17 Even with coronary artery bypass grafting
alone, IMR is not corrected in most cases and leaves
many patients with significant residual MR, as shown
by Aklog and colleagues18 in a series of 136 patients.18
Therefore, guidelines of societies recommend surgical
treatment for patients with symptomatic severe FMR, but
they do not indicate whether to repair or replace the MV.4
On decision-making in case of FMR, the surgeon has to
balance between a lower operative morbidity and mortality
in case of MV repair and a better long-term correction of
MR in case of valve replacement. In a recent published
meta-analysis by Vassileva and colleagues,5 MVR for
IMR is associated with better short- and long-term survival
compared with MV replacement. On the other hand,
Murphy and colleagues19 stated in a review article that
there is no convincing evidence that repair is superior to
replacement in case of surgery for IMR.
The operative mortality of 5.9% in our study population
is comparable to other reported rates ranging from 3.8% to
12%.20-22 In 2011, De Bonis and co-workers23 first
published retrospective data concerning the Edwards
GeoForm annuloplasty ring in 74 patients with ischemic
or dilated cardiomyopathy. The hospital mortality was
9.4%, and the overall survival was 81.1%  6.6% at
3.5 years.23 This is also comparable to our data, in which180 The Journal of Thoracic and Cardiovascular SurgKaplan–Meier analysis revealed 71.3%  6.9% overall
survival at 5 years after MV repair with the Edwards
GeoForm annuloplasty ring.
Another study published by De Bonis and colleagues24
reported an overall survival of 73.0% 10.9% at 3.7 years
in 79 patients undergoing MV repair in ischemic or
dilated cardiomyopathy. A complete rigid or semirigid
undersized ring annuloplasty (with or without edge-to-
edge technique) was used in their study.24 In a retrospective
study performed on 257 consecutive patients, Crabtree and
colleagues21 reported a 68.3% actuarial 3-year survival,
which is similar to our results, especially examining
patients with IMR.
In a retrospective nonrandomized trial, McGee and
colleagues8 reported on a high-grade MR in 28% of
patients 6 months after MV annuloplasty for functional
IMR. These results were confirmed in the study by Crabtree
and colleagues,21 in which 28% of patients presented with
3þ to 4þMR 20  25 months after MV repair for IMR. In
both studies, mainly flexible rings or bands had been
used.8,21 Therefore, alternative approaches have been
attempted, for example, papillary muscle relocation.25 In
contrast, the combination of the edge-to-edge technique
with an undersized ring annuloplasty can significantly
improve the durability of the repair in patients with
end-stage dilated cardiomyopathy.20,24 Recurrent severe
mitral regurgitation was present in 3.7% of patients with
undersized ring annuloplasty and additional edge-to-edge
technique compared with 21.7% of patients with under-
sized ring annuloplasty only.20,24
In our study, cohort freedom from recurrence of MR
grade 3þ to 4þ (ie, moderate-severe and severe) was
92.5%  3.6% at 4 years and freedom from recurrence
of MR grade 2þ (ie, moderate) was 71.0%  8.7% at 4
years. These data are comparable to those of De Bonis
and colleagues.23 At 3.5 years, they demonstrated an
overall freedom from MR 3þ or greater of 85.1%  8%
and an overall freedom from MR 2þ or greater of
75.1%  8.6% in their retrospective data concerning the
Edwards GeoForm annuloplasty ring in patients with
ischemic or dilated cardiomyopathy.23 Taken together, our
data and the data of De Bonis and colleagues23 show a lower
percentage of patients presenting with MR 3þ or greater or
MR 2 or greater at 4 or 3.5 years postoperatively than
studies in which flexible rings or bands had been used.8,21
During follow-up, there were 1.9  0.9 echocardiographic
assessments per patient without taking into account the
echocardiographic assessment before hospital discharge
(postoperatively).
When comparing MR postoperatively and at latest
follow-up, there are only a few patients in whom MR
worsened over time. Four of the 9 patients with moderate
MR at follow-up already had moderate (2þ/4þ) MR at
hospital discharge, which remained stable over time.ery c July 2014
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postoperatively, but the patient refused reoperation.
Severe MR developed postoperatively in 3 patients of our
cohort. They required an MV-related reoperation 11 days, 6
months, and 7 months after the initial operation. The
indication for reoperation was recurrent MR caused by
posterior dehiscence of the GeoForm annuloplasty ring,
which was documented intraoperatively. The stress forces
on the posterior part of the ring (elevated P2 segment, 6
mm lift) caused by the downward pull of the enlarged LV
were responsible for the dehiscence. All of these events
occurred in the beginning of our experience with the
GeoForm annuloplasty ring. Thus, we now place additional
Teflon felt–reinforced sutures in the posterior part of the
ring. We emphasize the importance of exact placement of
the annuloplasty sutures deep and precisely into the mitral
annulus and the additional use of Teflon felt–reinforced
sutures in the posterior part of the ring (6-mm lift) to ensure
secure fixation.
Clinically relevant mitral stenosis was not detected,
whereas mean pressure gradients across the MV were
3.3  1.8 mm Hg across all ring sizes at the time of
follow-up. This was also confirmed by De Bonis and
colleagues23 in patients at rest and in a small number of
patients during exercise echocardiography.
Moreover, a significant clinical improvement was
documented in our patients, reflected by a significant
improvement in NYHA functional class. This was due to
not only our ring annuloplasty but also myocardial
revascularization and a postoperatively extended therapy
for congestive heart failure.
Study Limitations
This study was performed in a retrospective manner. Ef-
fects of the 3-dimensional annuloplasty ring on the left
ventricle after MV repair for ischemicMRwere not studied.
On the other hand, in case of LV remodeling, it is difficult to
differentiate what causes the effects: the 3-dimensional
annuloplasty ring itself, the repaired MV, the concomitant
procedures, or the congestive heart failure therapy.
Magnetic resonance imaging would be a suitable tool to
work out such issues, but most of these patients are not
suitable because of exclusion criteria (eg, previous
pacemaker or defibrillator implantation, AF, poor general
condition). The Maze procedure was performed in only
3 of 12 patients presenting with AF. The rationale for this
low rate of AF ablation was to avoid longer crossclamp
times in this sick patient population. We have now changed
our policy concerning this issue and try to treat all patients
with AF regardless of a patient’s principal diagnosis.
CONCLUSIONS
MVannuloplasty with the Edwards GeoForm ring in case
of ischemic cardiomyopathy shows low rates of recurrentThe Journal of Thoracic and Camitral regurgitation in the midterm and may lead to an
improvement of clinical and functional status of the
patients. The importance of secure anchoring of the device
in the mitral annulus has to be emphasized to prevent ring
dehiscence. Surgical intervention remains the mainstay of
therapy in these patients because the results with medical
management have not been favorable. In case of IMR, we
prefer 3-dimensional valve repair.References
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